Global first: first patient in a skin cancer study receives treatment at Maria Middelares General Hospital

In mid December, the first patient was treated as part of the E011-MEL study in which an innovative therapy was administered to melanoma patients. Malignant melanomas are tumours that affect the skin as well as mucosal membranes. Patients with advanced or metastatic forms of skin cancers receive standard immunotherapy. If their disease remains stable, we are then able to administer this innovative cell vaccination in the inguinal lymph nodes in addition to the standard treatment.

For more information, see the clinical studies of the Integrated Cancer Centre in Ghent (ICG)

Something wrong or unclear on this page? Report it.